Explore how AI is transforming drug discovery — from target ID to smarter clinical trials — cutting time and cost while improving patient outcomes. A concise outlook for healthcare leaders and investors.
AI Drug Discovery: How Machine Learning Is Speeding Up New Medicines Read More »
A concise, realistic guide to where AI adds measurable value in drug discovery: data enrichment, experiment prioritization, and multi-parameter optimization. Practical limits and steps for teams.
AI in Drug Discovery: Practical Value, Not Hype Read More »
How generative AI and protein structure prediction are shortening drug discovery timelines, with examples, practical impacts, and strategic considerations for pharma leaders.
Generative AI Meets Structure Prediction: Faster Drug Discovery for Pharma R&D Read More »
How Insilico Medicine’s Pharma.AI fuses foundation models, AI agents, Generative Biologics, Chemistry42, PandaClaw and MMAI Gym to speed drug discovery.
How AI is shortening drug discovery timelines, producing real candidates and reshaping R&D with examples from AlphaFold, Exscientia, BenevolentAI and Insilico.
AI’s Proven Track Record: Accelerating Drug Discovery from Lab to Life Read More »
Concise overview of AI in drug discovery: where it delivers, measurable early-stage gains, and the validation and reproducibility hurdles slowing broader adoption.
AI in Drug Discovery: Progress and Persistent Challenges Read More »
Agentic AI is reshaping drug discovery. Learn why specialized agents outperform general models, how they tackle preclinical toxicology, and how teams can start pilots today.
The Rise of Agentic AI: How Specialized Agents Are Accelerating Drug Discovery Read More »
London startup Perceptic raised $12M to build an AI operating system that unites fragmented pharma R&D workflows, speeding due diligence and clinical translation.
Perceptic’s AI Operating System Raises $12M to Unite Drug Discovery Read More »
QIAGEN and NVIDIA are combining QIAGEN Digital Insights with NVIDIA BioNeMo and graph-based AI to speed target ID, biomarker discovery and drug repurposing.
QIAGEN and NVIDIA Partner to Advance AI Drug Discovery Read More »
Isomorphic Labs raised $2.1 billion to scale its IsoDDE AI drug design engine. Backed by Thrive Capital, Alphabet, Temasek and the UK’s sovereign AI fund, the funding aims to speed therapeutic programs toward clinic.
Isomorphic Labs Secures $2.1B Series B to Accelerate AI Drug Discovery Read More »
